Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Clinical cancer research

Results: 51-75/3141

Authors: Gorschluter, M Ziske, C Glasmacher, A Schmidt-Wolf, IGH
Citation: M. Gorschluter et al., Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma, CLIN CANC R, 7(8), 2001, pp. 2195-2204

Authors: Veal, GJ Dias, C Price, L Parry, A Errington, J Hale, J Pearson, ADJ Boddy, AV Newell, DR Tilby, MJ
Citation: Gj. Veal et al., Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy, CLIN CANC R, 7(8), 2001, pp. 2205-2212

Authors: Hu, YC Lam, KY Law, S Wong, J Srivastava, G
Citation: Yc. Hu et al., Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: Overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC, CLIN CANC R, 7(8), 2001, pp. 2213-2221

Authors: Shao, ZM Wu, J Shen, ZZ Nguyen, M
Citation: Zm. Shao et al., p53 mutation in plasma DNA and its prognostic value in breast cancer patients, CLIN CANC R, 7(8), 2001, pp. 2222-2227

Authors: Munster, PN Basso, A Solit, D Norton, L Rosen, N
Citation: Pn. Munster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner -See The Biology Behind: E. A. Sausville, combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters. Clin. Cancer Res., 7: 2155-2158, 2001., CLIN CANC R, 7(8), 2001, pp. 2228-2236

Authors: Weeraratna, AT Dalrymple, SL Lamb, JC Denmeade, SR Miknyoczki, S Dionne, CA Isaacs, JT
Citation: At. Weeraratna et al., Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells, CLIN CANC R, 7(8), 2001, pp. 2237-2245

Authors: Wolff, RA Evans, DB Gravel, DM Lenzi, R Pisters, PWT Lee, JE Janjan, NA Charnsangavej, C Abbruzzese, JL
Citation: Ra. Wolff et al., Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma, CLIN CANC R, 7(8), 2001, pp. 2246-2253

Authors: Bornhauser, M Thiede, C Platzbecker, U Jenke, A Helwig, A Plettig, R Freiberg-Richter, J Rollig, C Geissler, G Lutterbeck, K Oelschlagel, U Ehninger, G
Citation: M. Bornhauser et al., Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients, CLIN CANC R, 7(8), 2001, pp. 2254-2262

Authors: Landau, HJ Poiesz, BJ Dube, S Bogart, JA Weiner, LB Souid, AK
Citation: Hj. Landau et al., Classic Kaposi's sarcoma associated with human herpesvirus 8 infection in a 13-year-old male: A case report, CLIN CANC R, 7(8), 2001, pp. 2263-2268

Authors: Muhr, C Gudjonsson, O Lilja, A Hartman, M Zhang, ZJ Langstrom, B
Citation: C. Muhr et al., Meningioma treated with interferon-alpha, evaluated with [C-11]-L-methionine positron emission tomography, CLIN CANC R, 7(8), 2001, pp. 2269-2276

Authors: Sadanaga, N Nagashima, H Mashino, K Tahara, K Yamaguchi, H Ohta, M Fujie, T Tanaka, F Inoue, H Takesako, K Akiyoshi, T Mori, M
Citation: N. Sadanaga et al., Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas, CLIN CANC R, 7(8), 2001, pp. 2277-2284

Authors: Stopeck, AT Jones, A Hersh, EM Thompson, JA Finucane, DM Gutheil, JC Gonzalez, R
Citation: At. Stopeck et al., Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta 2-microglobulin DNA-liposome complex, in patients with metastatic melanoma, CLIN CANC R, 7(8), 2001, pp. 2285-2291

Authors: Gilbert, J Baker, SD Bowling, MK Grochow, L Figg, WD Zabelina, Y Donehower, RC Carducci, MA
Citation: J. Gilbert et al., A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies, CLIN CANC R, 7(8), 2001, pp. 2292-2300

Authors: Zamboni, WC D'Argenio, DZ Stewart, CF MacVittie, T Delauter, BJ Farese, AM Potter, DM Kubat, NM Tubergen, D Egorin, MJ
Citation: Wc. Zamboni et al., Pharmacodynamic model of topotecan-induced time course of neutropenia, CLIN CANC R, 7(8), 2001, pp. 2301-2308

Authors: Spiro, TP Liu, L Majka, S Haaga, J Willson, JKV Gerson, SL
Citation: Tp. Spiro et al., Temozolomide: The effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O-6-alkylguanine-DNA-alkyltransferase, CLIN CANC R, 7(8), 2001, pp. 2309-2317

Authors: Liu, L Spiro, TP Qin, XS Majka, S Haaga, J Schupp, J Willson, JKV Gerson, SL
Citation: L. Liu et al., Differential degradation rates of inactivated alkyltransferase in blood mononuclear cells and tumors of patients after treatment with O-6-benzylguanine, CLIN CANC R, 7(8), 2001, pp. 2318-2324

Authors: Kelly, K Lovato, L Bunn, PA Livingston, RB Zangmeister, J Taylor, SA Roychowdhury, D Crowley, JJ Gandara, DR
Citation: K. Kelly et al., Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: A phase II trial of the southwest oncology group, CLIN CANC R, 7(8), 2001, pp. 2325-2329

Authors: Gore, SD Weng, LJ Zhai, S Figg, WD Donehower, RC Dover, GJ Grever, M Griffin, CA Grochow, LB Rowinsky, EK Zabalena, Y Hawkins, EK Burks, K Miller, CB
Citation: Sd. Gore et al., Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia, CLIN CANC R, 7(8), 2001, pp. 2330-2339

Authors: Straub, B Muller, M Krause, H Schrader, M Goessl, C Heicappell, R Miller, K
Citation: B. Straub et al., Increased incidence of luteinizing hormone-releasing hormone receptor genemessenger RNA expression in hormone-refractory human prostate cancers, CLIN CANC R, 7(8), 2001, pp. 2340-2343

Authors: Ghilardi, G Biondi, ML Mangoni, J Leviti, S DeMonti, M Guagnellini, E Scorza, R
Citation: G. Ghilardi et al., Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness, CLIN CANC R, 7(8), 2001, pp. 2344-2346

Authors: Michael-Robinson, JM Reid, LE Purdie, DM Biemer-Huttmann, AE Walsh, MD Pandeya, N Simms, LA Young, JP Leggett, BA Jass, JR Radford-Smith, GL
Citation: Jm. Michael-robinson et al., Proliferation, apoptosis, and survival in high-level microsatellite instability sporadic colorectal cancer, CLIN CANC R, 7(8), 2001, pp. 2347-2356

Authors: Guadagni, F Ferroni, P Carlini, S Mariotti, S Spila, A Aloe, S D'Alessandro, R Carone, MD Cicchetti, A Ricciotti, A Venturo, I Perri, P Di Filippo, F Cognetti, F Botti, C Roselli, M
Citation: F. Guadagni et al., A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: A prospective longitudinal study, CLIN CANC R, 7(8), 2001, pp. 2357-2362

Authors: Dong, Y Kaushal, A Bui, L Chu, S Fuller, PJ Nicklin, J Samaratunga, H Clements, JA
Citation: Y. Dong et al., Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas, CLIN CANC R, 7(8), 2001, pp. 2363-2371

Authors: Luo, LY Katsaros, D Scorilas, A Fracchioli, S Piccinno, R de la Longrais, IA Howarth, DJC Diamandis, EP
Citation: Ly. Luo et al., Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma, CLIN CANC R, 7(8), 2001, pp. 2372-2379

Authors: Obiezu, CV Scorilas, A Katsaros, D Massobio, M Yousef, GM Fracchioli, S de la Longrais, IAR Arisio, R Diamandis, EP
Citation: Cv. Obiezu et al., Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients, CLIN CANC R, 7(8), 2001, pp. 2380-2386
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>